In the second part of this two-video series, Guillermo Garcia-Manero, MD, continues his discussion of lower-risk myelodysplastic syndromes with SOHO young investigators during SOHO 2026.
This video includes the following discussion points:
- Response rates with luspatercept compared with erythropoiesis-stimulating agents in the COMMANDS trial
- Differences in response by ring sideroblast status, transfusion burden and EPO levels
- Long-term follow-up data on the duration of treatment response
- Emerging findings on overall survival and progression to higher-risk MDS
- Questions surrounding optimal luspatercept dosing and the management of adverse effects
In the first part of the two-video series, Dr. Garcia-Manero discusses the goals of therapy in lower-risk MDS and questions surrounding dosing and adverse effects.
Leave feedback about this